Last reviewed · How we verify
Ethynyl-estradiol plus cyproterone acetate
At a glance
| Generic name | Ethynyl-estradiol plus cyproterone acetate |
|---|---|
| Sponsor | Hospital Universitario Ramon y Cajal |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Functional Study of the Hypothalamus in Magnetic Resonance Imaging (MRI) in Polycystic Ovary Syndrome (PCOS) (NA)
- GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients (PHASE2, PHASE3)
- The Progression From Dysmenorrhoea to Chronic Pelvic Pain
- "Effect of CPA/EE Drug on Periodontal Tissue and hsCRP Levels in PCOS Patients With Gingivitis
- Study on Safety and Efficacy of an Oral Contraceptive in Treating Acne Papulopustulosa (PHASE3)
- Research on Risk Factors and Interventions of Polycystic Ovary Syndrome Complicated With Depression and Anxiety (NA)
- Phlebotomy and Polycystic Ovary Syndrome (NA)
- The Effect of Polycystic Ovary Syndrome Treatment on Metabolomics (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: